Literature DB >> 28011501

Laparoscopic versus Open Partial Nephrectomy: Comparison of Overall and Subgroup Outcomes.

Mohamed Abdelhafez1,2, Amend Bastian1, Steffen Rausch1, Arnulf Stenzl1, Jens Bedke3, Stephan Kruck1.   

Abstract

BACKGROUND: At experienced centers, laparoscopic partial nephrectomy (LPN) can achieve similar results to those of open surgery (OPN). However, the role of LPN for complex tumors and imperative indications is under debate. PATIENTS AND METHODS: A total of 356 cases (186 LPN and 170 OPN) between 2005-2012 were reviewed. Clinical, surgical, pathological and radiological data, including PADUA classification were analyzed.
RESULTS: In overall analysis, OPN was associated with higher tumor complexity (p≤0.03). Subgroup analysis of PADUA >8 tumors (n=85) showed no significant difference between LPN and OPN. In patients with unfavorable treatment characteristics (imperative indication/multifocal tumors, n=71) LPN was beneficial. In this subgroup, LPN led to better perioperative (p≤0.02) and postoperative (p≤0.04) outcome.
CONCLUSION: Use of LPN is associated with favorable tumor characteristics. Although no advantage was shown for LPN for tumors with higher complexity (PADUA>8), this large series confirmed the superiority of LPN for imperative indication or multifocal tumors. Copyright
© 2017 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Laparoscopy; partial nephrectomy; perioperative outcomes; renal cell carcinoma; renal score

Mesh:

Year:  2017        PMID: 28011501     DOI: 10.21873/anticanres.11316

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  A comparison of outcomes for standard and multiplex partial nephrectomy in a solitary kidney: The National Cancer Institute experience.

Authors:  Joseph A Baiocco; Mark W Ball; Asha K Pappajohn; Kareem N Rayn; Gennady Bratslavsky; Shawna L Boyle; William M Linehan; Adam R Metwalli
Journal:  Urol Oncol       Date:  2019-03-20       Impact factor: 3.498

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.